Identification of a New Gene Involved in Hereditary Lipodystrophy (LIPOGENE)

Identification of a New Gene Involved in Hereditary Lipodystrophy - LIPOGENE

Human lipodystrophies (lipoD) represent a heterogeneous group of diseases characterized by generalized or partial fat loss, with fat hypertrophy in other depots when partial.3, 4 Insulin resistance, dyslipidemia and diabetes are generally associated, leading to early complications. Acquired lipoD can be generalized, resembling congenital forms, or partial, as the Barraquer-Simons syndrome, with loss of fat in the upper part of the body contrasting with accumulation in the lower part. The most common forms of lipoD are iatrogenic. In human immunodeficiency virus-infected patients, some first-generation antiretroviral drugs were strongly related with peripheral lipoatrophy and metabolic alterations. Genetic forms are very uncommon: recessive generalized congenital lipoD result in most cases from mutations in the genes encoding seipin or the 1-acyl-glycerol-3-phosphate-acyltransferase 2 (AGPAT2). Dominant partial familial lipoD result from mutations in genes encoding the nuclear protein lamin A/C or the adipose transcription factor PPARgamma. Importantly, LMNA mutations are also responsible for metabolic laminopathies, resembling the metabolic syndrome and progeria, a syndrome of premature aging. Molecular genetic bases of many rare forms of genetic lipoD remain to be elucidated.

Study Overview

• Status: Completed
• Conditions: Lipodystrophy
• Intervention / Treatment: Genetic: Amplification by PCR and direct sequencing on the entire coding sequence and intron-exons boundaries of the candidate gene; Biological: Perform blood cells and fibroblasts biochemical and immuno-labeled investigations

Detailed Description

The investigators have recently evaluated two sisters (index patients) affected by a syndrome associating diffuse leukoencephalopathy and partial lipoD. The investigators have analyzed numerous known genetic causes of leukodystrophies and lipoD but the investigators failed to identify a known cause for this syndrome which has never been previously reported. The investigators then switched their effort to analyses of exome using next generation sequencing in both affected sisters and their unaffected relatives (one sister and two parents). The investigators identified an excellent candidate gene with a homozygous missense mutation in both affected sisters. The investigators now aim to prove the involvement of this candidate gene in lipoD's determinism by a search of additional mutations in the candidate gene in a series of patients affected with lipoD (collaboration with Pr Capeau's Team) (LIPOGENE study) and by functional analyses performed in the two index patients on blood and skin samples (LIPOGENE sub-study).

• Study Type: Interventional
• Enrollment (Actual): 2
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Bordeaux, France, 33076
    • Service de Génétique Médicale

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Study :

• Patients affected by lipoD
• No identified genetic cause of lipoD
• Child or adult
• DNA already available in the French reference laboratory for the genetic diagnosis of lipoD (laboratoire de Biochimie du CHU Saint-Antoine, Paris) or in the INSERM UMRS 938 laboratory, Faculté de médecine Pierre et Marie Curie Site Saint-Antoine, Paris
• Subject affiliated to the french Sécurité Sociale
• Signed consent obtained for the molecular diagnosis of lipoD.

Sub-study:

• Signed consent obtained for this sub-study from both index patients

Exclusion Criteria:

Study:

• Identified genetic cause of lipoD
• No signed consent by the patient
• Subject not affiliated to the french Sécurité Sociale.

Sub-study:

• Absence of signed consent obtained for this sub-study from both index patients

Study Plan

How is the study designed?

Design Details

• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
OTHER: Lipodystrophie Héréditaire	Genetic: Amplification by PCR and direct sequencing on the entire coding sequence and intron-exons boundaries of the candidate gene; Biological: Perform blood cells and fibroblasts biochemical and immuno-labeled investigations; Performed only in the two index patients enrolled in the sub-study

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Additional mutation in the studied candidate gene XX	Study's primary outcome	6 months
Altered lipids composition in blood red cells membranes	Sub-study's primary outcome	6 months
Quantitative or qualitative variation of the protein encoded by the candidate gene in fibroblasts	Sub-study's primary outcome	6 months
Dense deposits in fibroblasts cytoplasm	Sub-study's primary outcome	6 months
Phospholipids anomalies in plasma	Sub-study's primary outcome	6 months

Collaborators and Investigators

• Sponsor: University Hospital, Bordeaux
• Investigators: Principal Investigator: Marie-Laure VUILLAUME, University Hospital, Bordeaux

Study record dates

Study Major Dates

• Study Start: January 1, 2014
• Primary Completion (ACTUAL): January 1, 2014
• Study Completion (ACTUAL): January 1, 2014

Study Registration Dates

• First Submitted: January 24, 2014
• First Submitted That Met QC Criteria: February 5, 2014
• First Posted (ESTIMATE): February 6, 2014

Study Record Updates

• Last Update Posted (ESTIMATE): January 14, 2015
• Last Update Submitted That Met QC Criteria: January 13, 2015
• Last Verified: January 1, 2015

More Information

Terms related to this study

• Keywords: lipodystrophy; gene; inborn error of metabolism
• Additional Relevant MeSH Terms: Metabolic Diseases; Skin Diseases; Lipid Metabolism Disorders; Skin Diseases, Metabolic; Lipodystrophy
• Other Study ID Numbers: CHUBX 2013/13